AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28674856 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antiglaucoma medications)
Number of subjects: 257
Study 27401892 — intervention group
Group type: EXPERIMENTAL
Intervention: onartuzumab (10 mg/kg) plus mFOLFOX6
Number of subjects: 123
Study 27401892 — intervention group
Group type: COMPARATOR
Intervention: placebo plus mFOLFOX6
Number of subjects: 123
Study 27401892 — intervention group
Group type: EXPERIMENTAL
Intervention: onartuzumab (10 mg/kg) plus mFOLFOX6 in MET-positive population
Number of subjects: 123
Study 27401892 — intervention group
Group type: COMPARATOR
Intervention: placebo plus mFOLFOX6 in MET-positive population
Number of subjects: 123
Study 24919684 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% albumin plus furosemide
Number of subjects: 50
Study 24919684 — intervention group
Group type: COMPARATOR
Intervention: Furosemide alone (normal saline placebo)
Number of subjects: 50
Study 22450591 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiotaping (KT) for enhancing muscle strength
Number of subjects: 36
Study 22450591 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiotaping (KT) for inhibiting muscle strength
Number of subjects: 36
Study 22450591 — intervention group
Group type: COMPARATOR
Intervention: Sham Kinesiotaping (placebo)
Number of subjects: 36
Study 20860443 — intervention group
Group type: EXPERIMENTAL
Intervention: PW1 (final radiographic follow-up)
Number of subjects: 12
Study 20860443 — intervention group
Group type: EXPERIMENTAL
Intervention: PW2 (both postoperative follow-up and final follow-up)
Number of subjects: 12
Study 20860443 — intervention group
Group type: COMPARATOR
Intervention: RSA (Model‐based RSA using elementary geometrical shape models)
Number of subjects: 12
Study 20860443 — intervention group
Group type: EXPERIMENTAL
Intervention: PW1
Number of subjects: 12
Study 20860443 — intervention group
Group type: COMPARATOR
Intervention: RSA
Number of subjects: 12
Study 18242415 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritious supplement (atole)
Number of subjects: 1424
Study 18242415 — intervention group
Group type: COMPARATOR
Intervention: Less nutritious supplement (fresco)
Number of subjects: 1424
Study 16193892 — intervention group
Group type: EXPERIMENTAL
Intervention: Avonex® (interferon beta-la) 30 μg, intramuscular, once weekly
Number of subjects: 0
Study 12091066 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Quality of Life (QoL) above median (67)
Number of subjects: 501
Study 12091066 — intervention group
Group type: COMPARATOR
Intervention: Baseline Quality of Life (QoL) below median (67)
Number of subjects: 501
Study 10628579 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant therapy (tricyclic antidepressants, antiserotonin antidepressants, selective serotonin reuptake inhibitors, or multiple agents)
Number of subjects: 6595
Study 10628579 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant therapy
Number of subjects: 6595
Study 10628579 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 6595
Study 8787254 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-gauge needle
Number of subjects: 160
Study 8787254 — intervention group
Group type: COMPARATOR
Intervention: 25-gauge needle
Number of subjects: 160
Study 2025805 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Xylocaine
Number of subjects: 0
Study 2025805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6277018 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg given twice daily for 4 weeks
Number of subjects: 65
Study 6277018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 6277018 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine for a further 4-week period after initial treatment
Number of subjects: 65
Study 31936725 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly sprint interval training (SIT)
Number of subjects: 34
Study 31936725 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly sprint interval training (SIT)
Number of subjects: 34
Study 31936725 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 34
Study 31045666 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and volar plate fixation
Number of subjects: 92
Study 31045666 — intervention group
Group type: COMPARATOR
Intervention: Plaster immobilization
Number of subjects: 92
Study 28931010 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Number of subjects: 171
Study 27216240 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangshen Formula (TSF) plus irbesartan
Number of subjects: 144
Study 27216240 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus irbesartan
Number of subjects: 144
Study 24713285 — intervention group
Group type: EXPERIMENTAL
Intervention: VA group (sole VA supplementation)
Number of subjects: 445
Study 24713285 — intervention group
Group type: EXPERIMENTAL
Intervention: FE group (sole iron supplementation)
Number of subjects: 445
Study 24713285 — intervention group
Group type: EXPERIMENTAL
Intervention: VF group (combined VA and iron supplementation)
Number of subjects: 445
Study 24713285 — intervention group
Group type: EXPERIMENTAL
Intervention: VA group
Number of subjects: 445
Study 24713285 — intervention group
Group type: EXPERIMENTAL
Intervention: FE group
Number of subjects: 445
Study 24713285 — intervention group
Group type: EXPERIMENTAL
Intervention: VF group
Number of subjects: 445
Study 24713285 — intervention group
Group type: COMPARATOR
Intervention: CO group (control group, no supplementation)
Number of subjects: 445
Study 23154554 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg
Number of subjects: 811
Study 23154554 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid 4 mg
Number of subjects: 811
Study 19916344 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant massage intervention (approximately 2 months duration)
Number of subjects: 25
Study 19916344 — intervention group
Group type: COMPARATOR
Intervention: Control group (typical parent education curriculum)
Number of subjects: 25
Study 17709660 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrowband UV-B phototherapy
Number of subjects: 14
Study 17709660 — intervention group
Group type: COMPARATOR
Intervention: Control (nonirradiated body halves)
Number of subjects: 14
Study 15355358 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense pulsed light treatment
Number of subjects: 17
Study 15355358 — intervention group
Group type: COMPARATOR
Intervention: Control group (hydroquinone cream and sunscreens)
Number of subjects: 17
Study 12011721 — intervention group
Group type: EXPERIMENTAL
Intervention: HBO (100% oxygen at 253 kPa [2.5 ATA] for 60 min)
Number of subjects: 12
Study 12011721 — intervention group
Group type: COMPARATOR
Intervention: Sham (atmospheric air at 132 kPa [1.3 ATA] for 60 min)
Number of subjects: 12
Study 9833745 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine (600 mg/day)
Number of subjects: 22
Study 9833745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 9833745 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 22
Study 7865920 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental language training sessions (experimental group)
Number of subjects: 0
Study 7865920 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual, direct speech and language therapy (third group)
Number of subjects: 0
Study 7865920 — intervention group
Group type: COMPARATOR
Intervention: General learning skills training sessions (parental control group)
Number of subjects: 0
Study 2688528 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopromide
Number of subjects: 322
Study 2688528 — intervention group
Group type: COMPARATOR
Intervention: Ioxaglate
Number of subjects: 322
Study 1113235 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain triglyceride (MCT) formula
Number of subjects: 16
Study 1113235 — intervention group
Group type: COMPARATOR
Intervention: Long-chain triglyceride (LCT) formula
Number of subjects: 16
Study 30958045 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg octacosanol intake
Number of subjects: 26
Study 30958045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 28385303 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-education system (pretest, ROP tutorial, ROP educational chapters, and posttest)
Number of subjects: 58
Study 28385303 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-education system
Number of subjects: 58
Study 28385303 — intervention group
Group type: COMPARATOR
Intervention: Control group (pretest and posttest only)
Number of subjects: 58
Study 24890674 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate cream or ointment administered once or twice daily
Number of subjects: 0
Study 24890674 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 23745532 — intervention group
Group type: EXPERIMENTAL
Intervention: Underlay graft
Number of subjects: 195
Study 23745532 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlay graft
Number of subjects: 195
Study 23745532 — intervention group
Group type: EXPERIMENTAL
Intervention: Button graft
Number of subjects: 195
Study 20940336 — intervention group
Group type: EXPERIMENTAL
Intervention: PI-2301 (0.035 to 60 mg subcutaneous injection)
Number of subjects: 56
Study 20940336 — intervention group
Group type: EXPERIMENTAL
Intervention: PI-2301 (10, 30, and 60 mg cohorts)
Number of subjects: 56
Study 20940336 — intervention group
Group type: EXPERIMENTAL
Intervention: PI-2301 (1, 3, or 10 mg)
Number of subjects: 56
Study 20940336 — intervention group
Group type: EXPERIMENTAL
Intervention: PI-2301 (30 or 60 mg)
Number of subjects: 56
Study 19463459 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft (CABG)
Number of subjects: 1593
Study 19463459 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1593
Study 17963520 — intervention group
Group type: EXPERIMENTAL
Intervention: CT colonography
Number of subjects: 5025
Study 17963520 — intervention group
Group type: COMPARATOR
Intervention: Barium enema or colonoscopy (standard investigation)
Number of subjects: 5025
Study 15236997 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-hCG group (10000 IU hCG administered as soon as at least three follicles were >=17 mm on ultrasound)
Number of subjects: 413
Study 15236997 — intervention group
Group type: COMPARATOR
Intervention: Late-hCG group (10000 IU hCG administered 2 days after the criterion was met)
Number of subjects: 413
Study 11585881 — intervention group
Group type: EXPERIMENTAL
Intervention: L&W with tPA (4 mg)
Number of subjects: 40
Study 11585881 — intervention group
Group type: COMPARATOR
Intervention: Mechanical thrombolysis with PTD
Number of subjects: 40
Study 11585881 — intervention group
Group type: COMPARATOR
Intervention: L&W with urokinase (UK) (250,000 U)
Number of subjects: 40
Study 9824020 — intervention group
Group type: EXPERIMENTAL
Intervention: BiPAP S/T-D
Number of subjects: 27
Study 9824020 — intervention group
Group type: COMPARATOR
Intervention: Servo Ventilator 900C
Number of subjects: 27
Study 8030656 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenous saline)
Number of subjects: 126
Study 8030656 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Number of subjects: 126
Study 2656877 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime (CTZ)
Number of subjects: 175
Study 2656877 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime (CTZ) or Cefamandole (CFM)
Number of subjects: 175
Study 2656877 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 175
Study 30803387 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuronavigated rTMS
Number of subjects: 40
Study 30803387 — intervention group
Group type: COMPARATOR
Intervention: Non-navigated rTMS
Number of subjects: 40
Study 30803387 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 28208688 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Restricted (SR)
Number of subjects: 30
Study 28208688 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot and Sleep Restricted (HOT + SR)
Number of subjects: 30
Study 25607905 — intervention group
Group type: COMPARATOR
Intervention: Retinol 0.25%
Number of subjects: 65
Study 25607905 — intervention group
Group type: COMPARATOR
Intervention: Retinol 0.5%
Number of subjects: 65
Study 25607905 — intervention group
Group type: COMPARATOR
Intervention: Retinol 1.0%
Number of subjects: 65
Study 24320206 — intervention group
Group type: EXPERIMENTAL
Intervention: Bidirectional knotless barbed suture (Quill™‐0; Angiotech Pharmaceuticals, Inc.)
Number of subjects: 117
Study 24320206 — intervention group
Group type: COMPARATOR
Intervention: Standard sutures (extracorporeal poliglecaprone 25; Monocryl™‐1 or intracorporeal polyglactin 910; Vicryl™‐1)
Number of subjects: 117
Study 24320206 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 3 months, 6 months, and 1 year after surgery
Number of subjects: 117
Study 22078155 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (50 mg/mL, 5 mg per 0.1 mL, administered once in 1 nostril)
Number of subjects: 7
Study 22078155 — intervention group
Group type: COMPARATOR
Intervention: Intravenous midazolam (2.5 mg, infused over 10 seconds)
Number of subjects: 7
Study 18653268 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB treatment (valsartan, candesartan, losartan)
Number of subjects: 180
Study 18653268 — intervention group
Group type: COMPARATOR
Intervention: No ARB (control)
Number of subjects: 180
Study 18653268 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB treatment
Number of subjects: 180
Study 15071279 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 0
Study 15071279 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study 10195713 — intervention group
Group type: EXPERIMENTAL
Intervention: Paladai
Number of subjects: 100
Study 10195713 — intervention group
Group type: COMPARATOR
Intervention: Cup
Number of subjects: 100
Study 10195713 — intervention group
Group type: COMPARATOR
Intervention: Bottle
Number of subjects: 100
Study 7495191 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin as add-on therapy
Number of subjects: 0
Study 7495191 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin monotherapy
Number of subjects: 0
Study 7495191 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine monotherapy
Number of subjects: 0
Study 1369725 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (2 x 316.5 mg tablets daily with meals) for 6 months
Number of subjects: 94
Study 1369725 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 tablets daily during washout and treatment)
Number of subjects: 94
Study 463771 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha methyldopa
Number of subjects: 0
Study 463771 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 0
Study 30709958 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) monotherapy for 3 months
Number of subjects: 298
Study 30709958 — intervention group
Group type: EXPERIMENTAL
Intervention: Low baseline levels of C-reactive protein (CRP)
Number of subjects: 298
Study 30709958 — intervention group
Group type: EXPERIMENTAL
Intervention: Low baseline levels of leptin
Number of subjects: 298
Study 30709958 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline levels of tumor necrosis factor receptor I (TNF-RI)
Number of subjects: 298
Study 30709958 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline levels of vascular cell adhesion molecule 1 (VCAM-1)
Number of subjects: 298
Study 30709958 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined score based on CRP, leptin, TNF-RI, and VCAM-1
Number of subjects: 298
Study 28682289 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide (HP) 40%
Number of subjects: 26
Study 28682289 — intervention group
Group type: COMPARATOR
Intervention: Ozone (OZ)
Number of subjects: 26
Study 25939684 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic D2 lymphadenectomy
Number of subjects: 1050
Study 25939684 — intervention group
Group type: COMPARATOR
Intervention: Open D2 lymphadenectomy
Number of subjects: 1050
Study 23645886 — intervention group
Group type: EXPERIMENTAL
Intervention: ITCA 650 20 μg/day
Number of subjects: 286
Study 23645886 — intervention group
Group type: EXPERIMENTAL
Intervention: ITCA 650 40 μg/day
Number of subjects: 286
Study 23645886 — intervention group
Group type: COMPARATOR
Intervention: Ex-BID (twice-daily exenatide injections) 5 → 10 μg
Number of subjects: 286
Study 23645886 — intervention group
Group type: EXPERIMENTAL
Intervention: ITCA 650 60 μg/day
Number of subjects: 286
Study 23645886 — intervention group
Group type: EXPERIMENTAL
Intervention: ITCA 650 80 μg/day
Number of subjects: 286
Study 23645886 — intervention group
Group type: EXPERIMENTAL
Intervention: All ITCA 650 groups except 20 → 20 μg/day
Number of subjects: 286
Study 21873897 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 strength maintenance training session per week (group 2 + 1; n = 7)
Number of subjects: 14
Study 21873897 — intervention group
Group type: COMPARATOR
Intervention: 1 strength maintenance training session every second week (group 2 + 0.5; n = 7)
Number of subjects: 14
Study 21873897 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 14
Study 19678443 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma Desensitizer (Heraeus Kulzer)
Number of subjects: 52
Study 19678443 — intervention group
Group type: EXPERIMENTAL
Intervention: UltraEZ (Ultradent Products, Inc)
Number of subjects: 52
Study 19678443 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraphat (Colgate Oral Pharmaceuticals, Inc)
Number of subjects: 52
Study 19678443 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (placebo)
Number of subjects: 52
Study 17920503 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbst appliance
Number of subjects: 0
Study 17920503 — intervention group
Group type: COMPARATOR
Intervention: Begg appliance
Number of subjects: 0
Study 15284257 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC 100 (epirubicin 100 mg/m²)
Number of subjects: 150
Study 15284257 — intervention group
Group type: COMPARATOR
Intervention: FEC 50 (epirubicin 50 mg/m²)
Number of subjects: 150
Study 11528252 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN) >500 million units total dose
Number of subjects: 291
Study 11528252 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha (IFN) <=500 million units total dose
Number of subjects: 291
Study 11528252 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN) >500 million units total dose in patients with histology F2 or F3
Number of subjects: 291
Study 11528252 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha (IFN) duration <=24 weeks
Number of subjects: 291
Study 11528252 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha (IFN) duration >24 weeks
Number of subjects: 291
Study 9761101 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol
Number of subjects: 0
Study 9761101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7836521 — intervention group
Group type: EXPERIMENTAL
Intervention: Motile spermatozoa from subfertile men with sperm precursor excess
Number of subjects: 0
Study 7836521 — intervention group
Group type: COMPARATOR
Intervention: Motile spermatozoa from fertile controls
Number of subjects: 0
Study 7836521 — intervention group
Group type: EXPERIMENTAL
Intervention: Motile spermatozoa from subfertile men with leukocyte excess
Number of subjects: 0
Study 29322365 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron pots (Group A)
Number of subjects: 10
Study 29322365 — intervention group
Group type: COMPARATOR
Intervention: Aluminum pots (Group B)
Number of subjects: 10
Study 29322365 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 10
Study 27136892 — intervention group
Group type: EXPERIMENTAL
Intervention: Nostalgic reverie
Number of subjects: 0
Study 27136892 — intervention group
Group type: COMPARATOR
Intervention: Ordinary event writing
Number of subjects: 0
Study 24946227 — intervention group
Group type: EXPERIMENTAL
Intervention: ENRICH (Environmental Interventions in Children's Homes)
Number of subjects: 799
Study 24946227 — intervention group
Group type: EXPERIMENTAL
Intervention: High PA-promoting environments
Number of subjects: 799
Study 24946227 — intervention group
Group type: COMPARATOR
Intervention: Low PA-promoting environments
Number of subjects: 799
Study 22264616 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative education during child's surgical procedure
Number of subjects: 70
Study 22264616 — intervention group
Group type: COMPARATOR
Intervention: Postoperative education just before discharge home
Number of subjects: 70
Study 20836948 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized illustrations (flip chart)
Number of subjects: 189
Study 20836948 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized drawings
Number of subjects: 189
Study 20836948 — intervention group
Group type: EXPERIMENTAL
Intervention: Both standardized and individualized illustrations
Number of subjects: 189
Study 20836948 — intervention group
Group type: COMPARATOR
Intervention: Verbal information
Number of subjects: 189
Study 19422759 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (olanzapine, quetiapine, risperidone) combined with SSRI and cognitive-behavioral therapy (CBT) for 1 year
Number of subjects: 44
Study 19422759 — intervention group
Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitors (SSRIs) plus cognitive-behavioral therapy (CBT) for 1 year
Number of subjects: 44
Study 16683384 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed physiotherapy regimen of 19 exercises
Number of subjects: 60
Study 16683384 — intervention group
Group type: COMPARATOR
Intervention: Free physiotherapy following biomechanical physiological movements of the shoulder
Number of subjects: 60
Study 15385013 — intervention group
Group type: COMPARATOR
Intervention: Propofol (2.5 mg x kg(‐1) bolus followed by 100 microg x kg(‐1) x min(‐1) infusion)
Number of subjects: 43
Study 15385013 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1.5 mg x kg(‐1) bolus after 0.5 mg x kg(‐1) bolus of ketamine followed by 75 microg x kg(‐1) x min(‐1) infusion)
Number of subjects: 43